Smita Vaidya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Smita Vaidya has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
David Partlow
4 shared publicationsKristine Gugliuzza
4 shared publicationsTitus Barnes
3 shared publicationsMarcelo Fernandez-Vina
2 shared publicationsPedro Cano
2 shared publicationsSusan Sheldon
2 shared publications
Latest Publications
- 16 April 2012
- Published by Wiley in Clinical Transplantation
- Vol. 26 (6) , 853-856
Ten‐yr renal allograft survival of patients with antiphospholipid antibody syndrome
Background: Long‐term allograft survival of antiphospholipid antibody syndrome (APAS) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long‐term allograft survival ofAPAas well as patients withAPAS.Methods: During the study period fromJanuary 1, 1992 throughMay 31, 2009, 1625 patients withESRDawaiting renal transplants were screened forAPAS. Ninety‐four (5.8%) of these patients had circulating levels of anticardiolipin antibodies (ACA) and 39 of these patients had documented evidence of clotting disorders and were diagnosed withAPAS. Twenty‐one patients withAPASreceived transplants on either low molecular weight (LMW) heparin orCoumadin as anticoagulation therapy. Of 94 patients with onlyACA, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of eitherACAorAPASreceived renal transplants.Results: Ten‐yr allograft survival of patients withAPAStreated withCoumadin was similar to those treated withLMWheparin (18% vs. 20%,NS). However, those allograft survivals were significantly lower than those patients positive forACA(28%) alone (ACAvs.LMWheparin orCoumadin p = 0.0001).Conclusion: Despite anticoagulation therapies, patients withAPAShave lower long‐term graft survival than those patients who have circulatingACAbut noAPAS.
- 16 April 2012
- Published by Wiley in Clinical Transplantation
- Vol. 26 (6) , 853-856
Ten‐yr renal allograft survival of patients with antiphospholipid antibody syndrome
Background: Long‐term allograft survival of antiphospholipid antibody syndrome (APAS) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long‐term allograft survival ofAPAas well as patients withAPAS.Methods: During the study period fromJanuary 1, 1992 throughMay 31, 2009, 1625 patients withESRDawaiting renal transplants were screened forAPAS. Ninety‐four (5.8%) of these patients had circulating levels of anticardiolipin antibodies (ACA) and 39 of these patients had documented evidence of clotting disorders and were diagnosed withAPAS. Twenty‐one patients withAPASreceived transplants on either low molecular weight (LMW) heparin orCoumadin as anticoagulation therapy. Of 94 patients with onlyACA, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of eitherACAorAPASreceived renal transplants.Results: Ten‐yr allograft survival of patients withAPAStreated withCoumadin was similar to those treated withLMWheparin (18% vs. 20%,NS). However, those allograft survivals were significantly lower than those patients positive forACA(28%) alone (ACAvs.LMWheparin orCoumadin p = 0.0001).Conclusion: Despite anticoagulation therapies, patients withAPAShave lower long‐term graft survival than those patients who have circulatingACAbut noAPAS.
- 15 April 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 85 (7) , 1046-1050
Clinical Importance of Anti-Human Leukocyte Antigen-Specific Antibody Concentration in Performing Calculated Panel Reactive Antibody and Virtual Crossmatches
Background. Highly sensitized patients develop multi-human leukocyte antigen (HLA) specific antibodies. This study measures concentrations of anti-HLA antibodies in multispecific sera by converting fluorescence intensity into molecules of equivalent soluble fluorochrome (MESF) units. This was used to determine MESF units required for a positive T and B flow crossmatches (FLXM). Methods. MESF values of negative controls and sera from patients devoid of HLA antibodies were measured by FLXM and flow panel reactive antibody (PRA) screening beads. Fluorescence intensity values of anti-HLA specific antibodies determined by FlowPRA single antigen beads of highly sensitized patients were converted into MESF units. In addition, endpoint titers, MESF units, and % PRA of 26 sera were established. Results. MESF analysis accurately predicted the outcomes of 100% of T and B FLXM of sera with strong (MESF units>18,000) donor-specific antibody (DSA). The predictive values of T and B FLXM declined to 95% and 88% with weak DSA (6,000 MESF2,000). The graft survival at 1 year was 100% and there was no evidence of DSA posttransplant. Conclusion. MESF analysis is both a time and cost efficient way of measuring antibody strength. The strength of the antibody present in the sera of transplant candidates is critical for crossmatch prediction.
- 15 April 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 85 (7) , 1046-1050
Clinical Importance of Anti-Human Leukocyte Antigen-Specific Antibody Concentration in Performing Calculated Panel Reactive Antibody and Virtual Crossmatches
Background. Highly sensitized patients develop multi-human leukocyte antigen (HLA) specific antibodies. This study measures concentrations of anti-HLA antibodies in multispecific sera by converting fluorescence intensity into molecules of equivalent soluble fluorochrome (MESF) units. This was used to determine MESF units required for a positive T and B flow crossmatches (FLXM). Methods. MESF values of negative controls and sera from patients devoid of HLA antibodies were measured by FLXM and flow panel reactive antibody (PRA) screening beads. Fluorescence intensity values of anti-HLA specific antibodies determined by FlowPRA single antigen beads of highly sensitized patients were converted into MESF units. In addition, endpoint titers, MESF units, and % PRA of 26 sera were established. Results. MESF analysis accurately predicted the outcomes of 100% of T and B FLXM of sera with strong (MESF units>18,000) donor-specific antibody (DSA). The predictive values of T and B FLXM declined to 95% and 88% with weak DSA (6,000 MESF2,000). The graft survival at 1 year was 100% and there was no evidence of DSA posttransplant. Conclusion. MESF analysis is both a time and cost efficient way of measuring antibody strength. The strength of the antibody present in the sera of transplant candidates is critical for crossmatch prediction.
- 1 December 2007
- Published by Elsevier in Human Immunology
- Vol. 68 (12) , 947-949
DP reactive antibody in a zero mismatch renal transplant pair
- 1 December 2007
- Published by Elsevier in Human Immunology
- Vol. 68 (12) , 947-949
DP reactive antibody in a zero mismatch renal transplant pair
- 27 December 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (12) , 1606-1609
Pretransplant Soluble CD30 Is a Better Predictor of Posttransplant Development of Donor-Specific Antibodies and Acute Vascular Rejection than Panel Reactive Antibodies
This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA).Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA.AVR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36% versus 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% versus 5%, p = 0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93%) developed DSA posttransplant (p = 0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p = 0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p = 0.02).These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.
- 27 December 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (12) , 1606-1609
Pretransplant Soluble CD30 Is a Better Predictor of Posttransplant Development of Donor-Specific Antibodies and Acute Vascular Rejection than Panel Reactive Antibodies
This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA).Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA.AVR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36% versus 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% versus 5%, p = 0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93%) developed DSA posttransplant (p = 0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p = 0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p = 0.02).These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.
- 15 December 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (11) , 1524-1528
Prediction of Crossmatch Outcome of Highly Sensitized Patients by Single and/or Multiple Antigen Bead Luminex Assay
We used a solid-phase assay to identify human leukocyte antigen (HLA) Class I and II specificities in highly reactive sera, and applied this information to predict crossmatch outcome with greater than 90% accuracy. Sera from 20 highly sensitized end-stage renal disease patients reactive to 70-100% of HLA Class I and II antigen panel were analyzed by single and/or multiple antigen flow microparticle bead assay using Luminex platform (Luminex assay). These sera contained antibodies directed against high frequency public HLA class I and/or II epitopes accounting for 70-100% of serum's total reactivity. More than 2,000 complement dependent cytotoxicity (CDC) and 200 flow crossmatches (FLXM) were performed using sera from these patients and deceased donor T and B lymphocytes. Luminex serum analysis was able to correctly predict outcomes of 95% of T and B cell FLXM. In contrast, predictive values for the CDC T and B cell crossmatches by Luminex serum analysis were only 77% and 75%, respectively. The use of serum analysis in donor selection would have reduced the total number of required FLXM by more than 50%. The frequency of negative T cell FLXM was 56% when donors were selected randomly; however, if serum antibody analysis had been used to preselect the donors by excluding donors that were likely to be positive, the frequency of corresponding negative crossmatches would have increased up to 93%. This approach to donor selection may allow wider geographic sharing of cadaver donor organs without actually performing the crossmatch.
- 15 December 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (11) , 1524-1528
Prediction of Crossmatch Outcome of Highly Sensitized Patients by Single and/or Multiple Antigen Bead Luminex Assay
We used a solid-phase assay to identify human leukocyte antigen (HLA) Class I and II specificities in highly reactive sera, and applied this information to predict crossmatch outcome with greater than 90% accuracy. Sera from 20 highly sensitized end-stage renal disease patients reactive to 70-100% of HLA Class I and II antigen panel were analyzed by single and/or multiple antigen flow microparticle bead assay using Luminex platform (Luminex assay). These sera contained antibodies directed against high frequency public HLA class I and/or II epitopes accounting for 70-100% of serum's total reactivity. More than 2,000 complement dependent cytotoxicity (CDC) and 200 flow crossmatches (FLXM) were performed using sera from these patients and deceased donor T and B lymphocytes. Luminex serum analysis was able to correctly predict outcomes of 95% of T and B cell FLXM. In contrast, predictive values for the CDC T and B cell crossmatches by Luminex serum analysis were only 77% and 75%, respectively. The use of serum analysis in donor selection would have reduced the total number of required FLXM by more than 50%. The frequency of negative T cell FLXM was 56% when donors were selected randomly; however, if serum antibody analysis had been used to preselect the donors by excluding donors that were likely to be positive, the frequency of corresponding negative crossmatches would have increased up to 93%. This approach to donor selection may allow wider geographic sharing of cadaver donor organs without actually performing the crossmatch.
- 31 October 2006
- Published by Elsevier in Human Immunology
- Vol. 67, S46
50-W: Molecular basis for positive flow B cell crossmatch resulting from DR/DP cross-reactivity in a zero mismatch transplant pair
- 31 October 2006
- Published by Elsevier in Human Immunology
- Vol. 67, S46
50-W: Molecular basis for positive flow B cell crossmatch resulting from DR/DP cross-reactivity in a zero mismatch transplant pair
- 5 July 2006
- Published by Wiley in Clinical Transplantation
- Vol. 20 (4) , 461-464
Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies
Background: In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant. Methods: Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitor-based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA). Results: Overall AR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36% vs. 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% vs. 5%, p = 0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93%) developed DSA post-transplant (p = 0.001). Conclusion: These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.
- 5 July 2006
- Published by Wiley in Clinical Transplantation
- Vol. 20 (4) , 461-464
Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies
Background: In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant. Methods: Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitor-based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA). Results: Overall AR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36% vs. 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% vs. 5%, p = 0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93%) developed DSA post-transplant (p = 0.001). Conclusion: These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.
- 1 March 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (2) , 648-649
Synthesis of New and Memory HLA Antibodies From Acute and Chronic Rejections Versus Pregnancies and Blood Transfusions
- 1 March 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (2) , 648-649
Synthesis of New and Memory HLA Antibodies From Acute and Chronic Rejections Versus Pregnancies and Blood Transfusions
- 1 March 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (2) , 650-651
Management of End-Stage Renal Disease Patients With Antiphospholipid Antibody Syndrome
- 1 March 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (2) , 650-651
Management of End-Stage Renal Disease Patients With Antiphospholipid Antibody Syndrome
- 1 April 2004
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (7) , 1046-1049
EFFICACY OF ANTICOAGULATION THERAPY IN END-STAGE RENAL DISEASE PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME
End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high risk for the development of renal thrombosis without the benefit of anticoagulation therapy. This study examines the efficacy of anticoagulation therapy in this high-risk patient population. Of nine APAS renal-transplant patients, seven were treated with coumadin, whereas two were treated with heparin. Of the two patients treated with heparin, one had early allograft loss, whereas the other patient is doing fine at 5 years posttransplant. Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years posttransplant, two had early allograft loss, the remaining three patients returned to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because of bleeding complications. Anticoagulation therapy is beneficial to some but not all APAS patients. In addition, bleeding complications are a serious side effect of this therapy.
- 1 April 2004
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (7) , 1046-1049
EFFICACY OF ANTICOAGULATION THERAPY IN END-STAGE RENAL DISEASE PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME
End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high risk for the development of renal thrombosis without the benefit of anticoagulation therapy. This study examines the efficacy of anticoagulation therapy in this high-risk patient population. Of nine APAS renal-transplant patients, seven were treated with coumadin, whereas two were treated with heparin. Of the two patients treated with heparin, one had early allograft loss, whereas the other patient is doing fine at 5 years posttransplant. Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years posttransplant, two had early allograft loss, the remaining three patients returned to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because of bleeding complications. Anticoagulation therapy is beneficial to some but not all APAS patients. In addition, bleeding complications are a serious side effect of this therapy.